Evidence map›Paper›PMID 21203397›Full record

ArticlePloS one2010

Bcr/Abl interferes with the Fanconi anemia/BRCA pathway: implications in the chromosomal instability of chronic myeloid leukemia cells.

Antonio Valeri, Maria Eugenia Alonso-Ferrero, Paula Río, María Roser Pujol, José A Casado, Laura Pérez, Ariana Jacome, Xabier Agirre, Maria José Calasanz, Helmut Hanenberg and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. DNA damage response and hematological malignancy.International journal of hematology · 2017
    Review
  3. Article
  4. Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016
    Article
  5. Review
  6. Article
  7. Genomic instability in chronic myeloid leukemia: targets for therapy?Current hematologic malignancy reports · 2012
    Article
  8. Article
  9. Fanconi anaemia: from a monogenic disease to sporadic cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Antonio ValeriCentro de Investigaciones Energéticas, Medioambientales y Tecnológicas and Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.
Maria Eugenia Alonso-Ferrero
Paula Río
María Roser Pujol
José A Casado
Laura Pérez
Ariana Jacome
Xabier Agirre
Maria José Calasanz
Helmut Hanenberg
Jordi Surrallés
Felipe Prosper
Beatriz Albella
Juan A Bueren
Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas · ESCentre for Biomedical Network Research on Rare Diseases · ESClinica Universidad de Navarra · ESRiley Hospital for Children · USUniversitat Autònoma de Barcelona · ES

Funding

Genetic Therapy for Fanconi AnemiaR01CA155294 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI CLAPP, DAVID W, HANENBERG, HELMUT · 2011 to 2015
$1.6M
NCI NIH HHS R01 CA155294
6 · The paper itself

Abstract

Chronic myeloid leukemia (CML) is a malignant clonal disorder of the hematopoietic system caused by the expression of the BCR/ABL fusion oncogene. Although it is well known that CML cells are genetically unstable, the mechanisms accounting for this genomic instability are still poorly understood. Because the Fanconi anemia (FA) pathway is believed to control several mechanisms of DNA repair, we investigated whether this pathway was disrupted in CML cells. Our data show that CML cells have a defective capacity to generate FANCD2 nuclear foci, either in dividing cells or after DNA damage. Similarly, human cord blood CD34(+) cells transduced with BCR/ABL retroviral vectors showed impaired FANCD2 foci formation, whereas FANCD2 monoubiquitination in these cells was unaffected. Soon after the transduction of CD34(+) cells with BCR/ABL retroviral vectors a high proportion of cells with supernumerary centrosomes was observed. Similarly, BCR/ABL induced a high proportion of chromosomal abnormalities, while mediated a cell survival advantage after exposure to DNA cross-linking agents. Significantly, both the impaired formation of FANCD2 nuclear foci, and also the predisposition of BCR/ABL cells to develop centrosomal and chromosomal aberrations were reverted by the ectopic expression of BRCA1. Taken together, our data show for the first time a disruption of the FA/BRCA pathway in BCR/ABL cells, suggesting that this defective pathway should play an important role in the genomic instability of CML by the co-occurrence of centrosomal amplification and DNA repair deficiencies.

Indexed as

Genes, BRCA1Antigens, CD34Cell Line, TumorCentrosomeChromosome AberrationsChromosomesCross-Linking ReagentsDNA DamageFanconi AnemiaFanconi Anemia Complementation Group D2 ProteinFusion Proteins, bcr-ablHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMicroscopy, FluorescenceRetroviridaeAntigens, CD34Cross-Linking ReagentsFANCD2 protein, humanFanconi Anemia Complementation Group D2 ProteinFusion Proteins, bcr-abl

Identifiers

PMID21203397
PMCPMC3011007
OpenAlexW2143942325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.